{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:22:35Z","timestamp":1695478955796},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.leukres.2009.01.042","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T08:59:18Z","timestamp":1236675558000},"page":"1604-1608","source":"Crossref","is-referenced-by-count":4,"title":["Long-term survival in chronic myelocytic leukemia after a first primary malignancy"],"prefix":"10.1016","volume":"33","author":[{"given":"Hermann","family":"Brenner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Gondos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Pulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.01.042_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/10428199809058378","article-title":"Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal","volume":"29","author":"Aguiar","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2009.01.042_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/bjc.1991.174","article-title":"Myeloid leukaemia following therapy for a first primary cancer","volume":"63","author":"Nandakumar","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-006-9460-0","article-title":"Leukemia following breast cancer: an international population-based study of 376,825 women","volume":"105","author":"Howard","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.leukres.2009.01.042_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2265.1995.tb02932.x","article-title":"Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature","volume":"43","author":"Shimon","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.leukres.2009.01.042_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V70.4.905.905","article-title":"Radiogenic leukemia revisited","volume":"70","author":"Moloney","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.042_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.beha.2006.10.006","article-title":"Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?","volume":"20","author":"Larson","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.leukres.2009.01.042_bib7","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.01.042_bib8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.042_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.01.042_bib10","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Limited-Use Data (1973\u20132004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission."},{"key":"10.1016\/j.leukres.2009.01.042_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2003.10.013","article-title":"Period analysis for \u2018up-to-date\u2019 cancer survival data: theory, empirical evaluation, computational realisation and applications","volume":"40","author":"Brenner","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/aje\/kwj243","article-title":"Up-to-date and precise estimates of cancer patient survival: model-based period analysis","volume":"164","author":"Brenner","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.leukres.2009.01.042_bib13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#","article-title":"An alternative approach to monitoring cancer patient survival","volume":"78","author":"Brenner","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.20.3.826","article-title":"Up-to-date long-term survival curves of patients with cancer by period analysis","volume":"20","author":"Brenner","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2009.01.042_bib15","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/ije\/31.2.456","article-title":"Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland","volume":"31","author":"Brenner","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.leukres.2009.01.042_bib16","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.leukres.2009.01.042_bib17","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I","article-title":"The relative survival rate","volume":"76","author":"Henson","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib18","unstructured":"Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute; 1959."},{"key":"10.1016\/j.leukres.2009.01.042_bib19","unstructured":"Arias E. United States life tables, 2000. vol. 51: Natl Vit Stat Rep;2002:1\u201339."},{"key":"10.1016\/j.leukres.2009.01.042_bib20","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.042_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.21032","article-title":"Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukaemia\u2014comparison with historic experience","volume":"103","author":"Kantarjian","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","article-title":"Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha","volume":"104","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.042_bib23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.01.042_bib24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.leukres.2005.10.015","article-title":"Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients","volume":"30","author":"Ramanarayanan","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2009.01.042_bib25","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/sj.bjc.6603797","article-title":"Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)","volume":"96","author":"Nilsson","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2009.01.042_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.urology.2006.12.006","article-title":"Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy","volume":"69","author":"Bajaj","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.leukres.2009.01.042_bib27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1464-410X.2006.06396.x","article-title":"A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy","volume":"98","author":"Lin","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.leukres.2009.01.042_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-004-3974-0","article-title":"A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer","volume":"90","author":"Modi","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.leukres.2009.01.042_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jcb.21432","article-title":"Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects","volume":"103","author":"Rocha","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.leukres.2009.01.042_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1475-2867-6-22","article-title":"Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer","volume":"6","author":"Taja-Chayeb","year":"2006","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.leukres.2009.01.042_bib31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00535-007-2009-0","article-title":"Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate","volume":"42","author":"Itsukuma","year":"2007","journal-title":"J Gastroenterol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T14:06:35Z","timestamp":1589637995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0145212609000575"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.01.042","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}